Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BaseTIL-03M: TILs and ANV419 in Advanced Melanoma
NCT05869539Phase 1Active, not recruiting
- Sponsor
- University Hospital Basel
- Start
- Jun 2023
- Primary completion
- Apr 2026
- Modality
- Antibody Conjugates, Cell Therapies, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ANV419 and GC101 TIL + pembrolizumab in melanoma, sponsored by University Hospital Basel. Primary endpoints: Incidence of adverse events at 1 year, Frequency of adverse events at 1 year and 1 more. Started Jun 2023; status: active, not recruiting.
02
Drugs
ANV419GC101 TIL + pembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05869539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05869539.